Simcere Pharma Receives $503 Million Buyout Offer from Chairman
Simcere Pharma, a Nanjing maker of branded generics and proprietary drugs, has joined the stampede of China pharmaceutical companies that may go private. The company, which posted 2012 revenues of $334 million last week, received an offer of $9.56 per ADS from its chairman and several related entities. The offer values Simcere at $503 million and represents a premium of 19% from the close on Friday. Simcere has formed a number of very interesting partnerships, whose payoffs, if they occur, remain in the future. More details.... Stock Symbol: (NYSE: SCR) Share this with colleagues: // //  
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here